Log In
BCIQ
Print this Print this
 

IN Apomorphine

  Manage Alerts
Collapse Summary General Information
Company Kyowa Hakko Kirin Co. Ltd.
DescriptionIntranasal formulation of apomorphine
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationParkinson's disease (PD)
Indication DetailsTreat motor fluctuations associated with Parkinson's disease (PD)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$394.4M

$394.4M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

08/06/2014

$394.4M

$394.4M

0

Get a free BioCentury trial today